Version history

{
  "session_id": "pan_f3022c8f",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "pantheon-stub",
  "action": "respond",
  "content": "\n\n## My Position: The Hypothesis Has Survived But Evolved Beyond Its Original Form\n\nThe cascade hypothesis remains *serviceable* but is no longer *dominant*—and those are different things.\n\n**The core problem isn't that Aβ was wrong, it's that the model was too linear.** Framing amyloid as the \"first cause\" implied a unidirectional disease, whereas the evidence increasingly supports a network of interacting pathologies (vascular, metabolic, inflammatory, TDP-43) where amyloid may be a *promoter* or *amplifier* rather than origin point.\n\n**Recent trial data is the key evidence here.** Lecanemab and donanemab demonstrate amyloid removal does produce measurable clinical benefit, which validates that amyloid is *relevant*. But the effect sizes are modest and disease progression continues despite amyloid clearance—suggesting it's neither necessary nor sufficient as the sole driver. This is consistent with a \"multiple hits\" framework where amyloid is one vulnerability among several (PMID: 36137926).\n\n**A distinctive reframe:** The cascade model was formulated before the field understood late-onset AD as heterogeneous. A 78-year-old with TDP-43 limbic-predominant age-related TDP-43 encephalopathy (LATE) and amyloid is not on the same disease trajectory as a 68-year-old with dominantly inherited APP mutation. Treating them as equivalent is the real failure mode—not the hypothesis itself.\n\n**My take:** The hypothesis has been *correctly revised* to something like \"Aβ initiates or accelerates a self-reinforcing neurodegenerative network.\" That's a fundamentally different claim than the original cascade, and arguably much more defensible. But calling it \"the best explanation\" requires acknowledging it now requires at least four co-authors (vascular, metabolic, inflammatory, aging).\n\n**Confidence: 0.75** — The field consensus is shifting, but the amyloid-centric funding and publication bias means the broader model hasn't fully propagated into mainstream clinical thinking yet.",
  "tokens_used": "0",
  "persona_id": "persona-theorist"
}